Welcome New Associate Editors to JTGG！

Prof. Qingyi Wei

Prof. Qingyi Wei is the Director and Senior Researcher at the Cancer Prevention and Treatment Research Institute of the Guangdong-Hong Kong-Macao Greater Bay Area Institute of Precision Medicine (Guangzhou). He holds several prestigious titles, including Overseas Distinguished Young Scholar, Changjiang Scholar Chair Professor, and Chief Scientist of China's National "973" Program. Prof. Wei has also been recognized under the National High-Level Talent Recruitment Program. Over the years, Prof. Wei has focused on identifying biomarkers of cancer susceptibility and advancing research in cancer molecular epidemiology. His work has led to significant achievements in understanding and preventing lung, esophageal, gastric, liver, and colorectal cancers. His research aims to elucidate the molecular mechanisms of cancer development, identify high-risk populations and individuals, and improve prognostic assessments for cancer patients.

Prof. Wei has made pivotal contributions to elucidating genetic susceptibility to cancers and the molecular mechanisms of environmental carcinogenesis. His studies have clarified how impaired DNA repair functions lead to DNA damage and cancer development. These findings have been widely applied in molecular epidemiology, providing crucial insights into the etiology and prevention strategies for skin, lung, and oral cancers.

Prof. Wei previously served as the Deputy Director of the Duke University Medical Center’s Cancer Research Institute and is a Fellow of the American College of Epidemiology. He has also been a long-term member of multiple NIH grant review panels and has held editorial roles, including Editor-in-Chief, Associate Editor, and Editorial Board member for five international journals in molecular epidemiology and medicine. Prof. Wei also serves as a reviewer for over 20 specialized journals. To date, he has published more than 670 academic papers, which have amassed over 32,000 citations, highlighting his profound impact and influence in cancer etiology and prevention research.

Prof. Hani Gabra

Prof. Hani Gabra has held numerous prestigious positions, including Professor of Medical Oncology, Director of the Department of Medical Oncology, Chair of the Cancer Research Committee, Director of the Ovarian Cancer Action Research Centre, Deputy Director of the Imperial College Cancer Centre, and Head of the Gynecological Cancer Service at Imperial College London. He has also served as a member of the UK Cancer Research UK (CRUK) Grant Committee and the French National Cancer Research Funding Committee.

In addition to his academic roles, Prof. Gabra has been instrumental in translational medical research, serving as Deputy Director and Head of the Cancer Department at the NIHR North West London Clinical Research Network. His expertise extends to clinical drug development, where he has held senior roles, including Vice President of Early Clinical Development at AstraZeneca, Chief Medical Officer and Head of Clinical Development at BerGenBio, and founder of the US-based biotechnology company Papyrus Therapeutics. His research primarily investigates the molecular mechanisms underlying platinum-resistant ovarian cancer, exploring multiple targets such as AKT, mTOR, HDAC4, STAT1, and folate receptors. The targeted therapies he developed have successfully transitioned from laboratory research to clinical application. His work has been funded by organizations such as Ovarian Cancer Action, CRUK, the EU FP7 program, and various pharmaceutical companies.

To date, with over 180 SCI papers and more than 30,000 citations, Prof. Gabra has established himself as a leading figure in cancer etiology, treatment, and translational medicine. He also serves as Editor-in-Chief, Associate Editor, and Editorial Board member for several international journals in molecular epidemiology and medicine, and has reviewed manuscripts for more than 20 professional journals, fostering global academic exchange and collaboration in the field of oncology.

We are confident that the addition of Prof. Qingyi Wei and Prof. Hani Gabra as Associate Editors will elevate JTGG to new heights. Their expertise and leadership will further enhance the journal's academic rigor and its role as an inclusive platform for global researchers. We eagerly anticipate the innovative contributions they will bring to the fields of genomics and translational medicine.